<code id='C566A4A463'></code><style id='C566A4A463'></style>
    • <acronym id='C566A4A463'></acronym>
      <center id='C566A4A463'><center id='C566A4A463'><tfoot id='C566A4A463'></tfoot></center><abbr id='C566A4A463'><dir id='C566A4A463'><tfoot id='C566A4A463'></tfoot><noframes id='C566A4A463'>

    • <optgroup id='C566A4A463'><strike id='C566A4A463'><sup id='C566A4A463'></sup></strike><code id='C566A4A463'></code></optgroup>
        1. <b id='C566A4A463'><label id='C566A4A463'><select id='C566A4A463'><dt id='C566A4A463'><span id='C566A4A463'></span></dt></select></label></b><u id='C566A4A463'></u>
          <i id='C566A4A463'><strike id='C566A4A463'><tt id='C566A4A463'><pre id='C566A4A463'></pre></tt></strike></i>

          focus

          focus

          author:explore    Page View:2
          Two researchers look at a computer monitor showing a graph and other data
          Adobe

          Research universities are voicing concerns over some proposed changes to the process for reviewing scientific misconduct allegations, citing worries that new government requirements would hobble their own independent procedures and constitute a huge administrative burden.

          Nearly two decades since it last released research misconduct rules, the U.S. Office of Research Integrity (ORI) is ready to update its requirements for ensuring the scientific standards of projects funded by the U.S. Department of Health and Human Services, including the National Institutes of Health.

          advertisement

          The proposed changes, published on Oct. 6, include a new formal process that institutions would follow in reviewing allegations, a 30-day deadline for institutions to assess allegations, and provisions that make it harder to quickly dismiss cases that institutions believe to be “honest errors.”

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          comprehensive

          Alkermes shareholders re
          Alkermes shareholders re

          MarkLennihan/APAlkermesshareholdersvotedThursdaytore-electallofthedrugmaker’scurrentdirectors,ending

          read more
          The Readout: Amylyx, Alumis, and Lundbeck drug updates
          The Readout: Amylyx, Alumis, and Lundbeck drug updates

          AdobeWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechnewsletterinyo

          read more
          How one medical school became remarkably diverse
          How one medical school became remarkably diverse

          ThefirstclassattheUniversityofCalifornia,Davismedicalschool,in1972,waspredominantlywhiteandmale.Chri

          read more

          Novo Nordisk gets FDA approval to tout heart benefits of Wegovy

          AmandaAndrade-Rhoades/APU.S.regulatorsapprovedalabelexpansionforNovoNordisk’sobesitydrugWegovytotout